Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology

Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology

IntroductionCompared with breast cancer (BC) in women, BC in men is a rare disease with genetic and molecular peculiarities. Therapeutic approaches for male BC (MBC) are currently extrapolated from the clinical management of female BC, although the disease does not exactly overlap in males and femal...

Full description

Bibliographic Details
Main Authors:	Virginia Valentini, Valentina Silvestri, Agostino Bucalo, Giulia Conti, Mina Karimi, Linda Di Francesco, Giulia Pomati, Silvia Mezi, Bruna Cerbelli, Maria Gemma Pignataro, Arianna Nicolussi, Anna Coppa, Giulia D’Amati, Giuseppe Giannini, Laura Ottini
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-01-01
Series:	Frontiers in Oncology
Subjects:	male breast cancer (MBC) tumor profiling targeted gene panel sequencing clinically actionable genetic variants tumor mutational burden (TMB) microsatellite instability (MSI)
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1092201/full

Similar Items

Pan-Cancer Analysis of PIMREG as a Biomarker for the Prognostic and Immunological Role
by: Hua Zhu, et al.
Published: (2021-09-01)

Comprehensive analysis of pan‐cancer reveals potential of ASF1B as a prognostic and immunological biomarker
by: Xinyao Hu, et al.
Published: (2021-10-01)

An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing
by: Richa Malhotra, et al.
Published: (2023-03-01)

A meta-analysis with systematic review: Efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer
by: Aya El Helali, et al.
Published: (2022-10-01)

Clinical Significance and Prognostic Value of Human Soluble Resistance-Related Calcium-Binding Protein: A Pan-Cancer Analysis
by: Jinguo Zhang, et al.
Published: (2021-11-01)

Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case Report
by: Katsuo Usuda, et al.
Published: (2020-06-01)

The Importance of Predictive Biomarkers and Their Correlation with the Response to Immunotherapy in Solid Tumors—Impact on Clinical Practice
by: Raluca Ioana Mihaila, et al.
Published: (2024-09-01)

Molecular heterogeneity in histomorphologic subtypes of lung adeno carcinoma represents a challenge for treatment decision
by: Tobias Kolb, et al.
Published: (2024-03-01)

Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy
by: Yuting Jia, et al.
Published: (2023-06-01)

Next-generation sequencing analysis of endometrial screening liquid-based cytology specimens: a comparative study to tissue specimens
by: Toshiaki Akahane, et al.
Published: (2020-07-01)

Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers
by: Timothy V. Pham, et al.
Published: (2021-10-01)

Pan-cancer analysis of COL15A1: an immunological and prognostic biomarker
by: Lei Zhu, et al.
Published: (2024-08-01)

Pan-cancer analyses reveal IGSF10 as an immunological and prognostic biomarker
by: Yongxia Zhou, et al.
Published: (2023-01-01)

Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker
by: Xin Cheng, et al.
Published: (2021-02-01)

Microsatellite instability: a review of what the oncologist should know
by: Kai Li, et al.
Published: (2020-01-01)

Tertiary lymphoid structures’ pattern and prognostic value in primary adenocarcinoma of jejunum and ileum
by: Minying Deng, et al.
Published: (2024-09-01)

Analysis of Pan-Cancer Revealed the Immunological and Prognostic Potential of CBX3 in Human Tumors
by: Haitao Xu, et al.
Published: (2022-04-01)

The Identification of Necroptosis-Related Subtypes, the Construction of a Prognostic Model, and the Characterization of the Tumor Microenvironment in Gliomas
by: Yueyang Ba, et al.
Published: (2022-06-01)

PROTAC-mediated conditional degradation of the WRN helicase as a potential strategy for selective killing of cancer cells with microsatellite instability
by: Vikram Tejwani, et al.
Published: (2024-09-01)

High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
by: Saman Maleki Vareki
Published: (2018-12-01)

Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy
by: Xiangyu Yin, et al.
Published: (2024-11-01)

Immunotherapy in small bowel adenocarcinoma: a potential role?
by: Francesco Vitiello, et al.
Published: (2024-01-01)

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
by: Zijun Y. Xu-Monette, et al.
Published: (2017-12-01)

The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer
by: Yaxiong Zhang, et al.
Published: (2019-04-01)

Integrated analysis of NET‐DNA receptor CCDC25 in malignant tumors: Pan‐cancer analysis
by: Xianlin Cheng, et al.
Published: (2023-10-01)

Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer
by: Yuan‐sheng Zang, et al.
Published: (2019-08-01)

Microsatellite instability in gastric cancer: An institutional case series analysis in patients treated with neoadjuvant therapy
by: Laura Lorenzon, et al.
Published: (2024-03-01)

Improved NGS-based detection of microsatellite instability using tumor-only data
by: Ana Claudia Marques, et al.
Published: (2022-11-01)

Clinical relevance of the combined analysis of circulating tumor cells and anti-tumor T-cell immunity in metastatic breast cancer patients
by: Elena Muraro, et al.
Published: (2022-08-01)

Quantification of PD-L1 expression and tumor mutational burden in biologically distinct advanced pancreatic cancers responding to pembrolizumab: case reports
by: Kevin Y. Li, et al.
Published: (2024-12-01)

Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer
by: Li Zhang, et al.
Published: (2021-05-01)

STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma
by: Natalya Risinskaya, et al.
Published: (2022-05-01)

The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients
by: Shengjin Cui, et al.
Published: (2023-02-01)

Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma
by: Kai Ma, et al.
Published: (2022-11-01)

Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy
by: Shuhang Wang, et al.
Published: (2021-02-01)

Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
by: Paraskevi Vryza, et al.
Published: (2023-12-01)

Case report: Efficacy of immune checkpoint inhibitors for high tumour mutational burden malignant phyllodes tumours of the breast as revealed by comprehensive genomic profiling
by: Hiroo Katsuya, et al.
Published: (2025-02-01)

A novel BRCA2 splice variant identified in a young woman
by: Arianna Nicolussi, et al.
Published: (2020-12-01)

RARB associated with MSI, affects progression and prognosis of gastric cancer
by: Xufan Cai, et al.
Published: (2024-08-01)

Microsatellite instability testing in colorectal cancer using the QiaXcel advanced platform
by: Isabel Förster, et al.
Published: (2018-04-01)